November 2-4 in Boston
See daily releases from CTAD 2016
EXPEDITION 3: A phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer’s Disease
are now available
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge.
+ 33 (0)4 67 10 92 23